ERBB2 and non-small cell lung carcinoma: Neratinib, a pan-HER TKI, was evaluated in the phase II SUMMIT basket trial, in patients with refractory HER2-mutant NSCLC, achieving a partial response in only one patient (ORR 3.8%) [32].